Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents

Leukemia Research

Volumn 41, Issue , 2016, Pages 43-47

  Nazha, Aziz ^a   Sekeres, Mikkael A ^a   Garcia Manero, Guillermo ^b   Barnard, John ^c   Al Ali, Najla H ^d   Roboz, Gail J ^e   Steensma, David P ^f   DeZern, Amy E ^g   Zimmerman, Cassie ^a   Jabbour, Elias J ^b   Zell, Katrina ^c   List, Alan F ^d   Kantarjian, Hagop M ^b   Maciejewski, Jaroslaw P ^a   Komrokji, Rami S ^d  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^e NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Hypomethylating agent; MDS; Response; Stable disease

Indexed keywords

AZACITIDINE; DECITABINE; HEMATOLOGIC AGENT; HYPOMETHYLATING AGENT; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIMETABOLITE;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLAST CELL; CANCER GROWTH; CLINICAL TRIAL; DRUG RESPONSE; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHYSICAL DISEASE; PRIORITY JOURNAL; REMISSION; RISK ASSESSMENT; STABLE DISEASE; TREATMENT DURATION; TREATMENT OUTCOME; VERY ELDERLY; ANALOGS AND DERIVATIVES; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MYELODYSPLASTIC SYNDROMES;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84957846314     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2015.12.007     Document Type: Article

References (12)

1. Sekeres M.A., Cutler C. How we treat higher-risk myelodysplastic syndromes. Blood 2014, 123:829-836.
2. Garcia-Manero G. Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management. Am. J. Hematol. 2014, 89:97-108.
3. Bejar R., Tiu R.V., Sekeres M.A., Komrokji R.S. Myelodysplastic syndromes: recent advancements in risk stratification and unmet therapeutic challenges. American Society of Clinical Oncology Educational Book/ASCO American Society of Clinical Oncology Meeting 2013 2013.
4. Silverman L.R., Demakos E.P., Peterson B.L., et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J. Clin. Oncol. 2002, 20:2429-2440.
5. Kantarjian H., Issa J.P., Rosenfeld C.S., et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006, 106:1794-1803.
6. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009, 10:223-232.
7. List A.F., Fenaux P., Mufti G.J., Hellström-Lindberg E., Gore S., Bennett J.M., Silverman L.R., Backstrom J., Allen A.R., Beach C.L. Azacitidine (AZA) extends overall survival in higher-risk myelodysplastic syndromes (MDS) without necessity for complete remission. J. Clin. Oncol. 2008, 26(155):7006.
8. Cheson B.D., Greenberg P.L., Bennett J.M., et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006, 108:419-425.
9. Gore S.D., Fenaux P., Santini V., et al. A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial. Haematologica 2013, 98:1067-1072.
10. Silverman L.R., Fenaux P., Mufti G.J., et al. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. Cancer 2011, 117:2697-2702.
11. Lubbert M., Suciu S., Baila L., et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J. Clin.l Oncol. 2011, 29:1987-1996.
12. Greenberg P.L., Tuechler H., Schanz J., et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012, 120:2454-2465.